Novo Nordisk A/S

Diabetes and obesity are chronic conditions requiring ongoing prescription treatment; semaglutide medicines collectively generated approximately $34.6 billion in FY2025 with high patient retention once therapy is established. Forward visibility is meaningfully constrained, however: the company guided for a 5-13% CER revenue decline in 2026, driven by pricing dynamics and payer mix shifts that are difficult to forecast with precision.

Semaglutide-based products (Ozempic, Wegovy, Rybelsus) generated approximately $34.6 billion of $46.8 billion total FY2025 revenue, representing roughly 74% of total sales from a single molecule family. Diabetes care and obesity care combined represent approximately 94% of total sales, with only a small rare-disease segment providing any meaningful separation from the core therapeutic areas.

North American Operations represent approximately 55-60% of total company revenue, with the US market's list pricing and payer dynamics dominating the consolidated income statement. International Operations — EUCAN, APAC, Emerging Markets, and China — grew faster in FY2025 (14% at CER vs 8% CER for North America), but a single US policy change such as IRA drug price negotiation or Medicaid coverage cuts creates outsized company-wide impact.

Gross margin held at approximately 81% in FY2025, reflecting the high fixed-cost structure of pharmaceutical manufacturing at scale once capacity is established. GLP-1 biologics require capital-intensive aseptic manufacturing, and Novo's primarily debt-financed acquisition of Catalent's fill-and-finish facilities to address supply constraints demonstrates that incremental volume growth carries meaningful capital requirements, limiting pure operating leverage.

Insulin is life-sustaining for type 1 diabetics and is standard of care for type 2 diabetes management, making the diabetes segment highly non-discretionary. GLP-1 prescriptions for diabetes are supported by clinical treatment guidelines, while obesity drugs occupy a more discretionary position in payer coverage, though physician-driven prescription dynamics create repeat-purchase behavior more durable than typical consumer spending.